home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

FDA Compliant Handling of Out-of-Trend Results in Pharmaceutical Quality Control

 
  November 08, 2012  
     
 
ComplianceOnline, Online Event
2012-11-15


Why Should You Attend:

FDA's guidance on OOS test results requires failure investigations and other steps for Out-of-Specification (OOS) and Out-of-trend (OOT) results. While most companies are familiar with and have procedures for OOS results, this is not the case for OOT situations. The guide states: "Although the subject of this document is OOS results, much of the guidance may be useful for examining results that are out of trend". Managing OOT results also helps to avoid time consuming OOS results. The industry is unsure how to interpret and implement the FDA guidance.

This session will equip you with the knowledge and comprehensive understanding of FDA requirements for Out-of-Trend Results in pharmaceutical quality control.

Free Hand-outs:

For easy implementation, attendees will receive

  • SOPs:
    • Handling OOT results
    • Handling OOS results
    • Out-of-Specification Data Trending
  • Checklist: Handling OOT Situations

Areas Covered in this Webinar:

  • FDA regulations and guidelines.
  • FDA's final Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.
  • Difference between OOS and OOT results.
  • Developing SOPs for OOT situations and laboratory failures.
  • Investigating OOT results: what and how.
  • Retesting of OOT results.
  • Using historical data for OOT evaluation.
  • Using QC samples and product control charts for evaluation.
  • Developing corrective and preventive action plans.
  • Finding the root cause for OOT results.
  • Strategies to avoid OOS situations BEFORE they occur.
  • FDA compliant documentation of OOS, OOT, failure investigations, root causes and CAPA.

Who Will Benefit:

  • Analysts
  • Lab Supervisors and Managers
  • QA managers and personnel
  • Pharmaceutical R&D personnel
  • Documentation
  • Consultants
  • Contract laboratories
  • CROs
 
 
Organized by: Complianceonline
Invited Speakers: Ludwig Huber, Ph.D., is Director of Labcompliance and Chief Advisor for global FDA compliance for Agilent Technologies. He is the editor of www.labcompliance.com, the global on-line resource for validation and compliance issues for laboratories. He is the author of the books “Validation and Qualification in Analytical Laboratories, and "Validation of Computerized Analytical and Networked Systems", Informa Healthcare.
 
Deadline for Abstracts: 2012-11-14
 
Registration: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702540?channel=hummolgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.